<DOC>
	<DOC>NCT01693393</DOC>
	<brief_summary>Sandimmun optoral (Cyclosporin A) is used for the musculoskeletal manifestations of Primary Sjögren Syndrome</brief_summary>
	<brief_title>Low Dose Cyclosporin A in Primary Sjögren Syndrome</brief_title>
	<detailed_description>NSAR are used currently for the treatment of musculoskeletal manifestations at Sjögren Syndrome for the symptomatic release of pain. For therapy-resistant cases drugs also used in Rheumatoid Arthritis are used. For these drugs there is no registration for the treatment of Sjögren Syndrome.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>Diagnosis of a primary Sjögren´s Syndrome Liver values above 1,5 ULN uncontrolled arterial hypertension intraarticular or systemic use of Glucocorticoids in the last 4 weeks before begin with Study medication pretreatment with Cyclosporine A Infection Neoplasia relevant cardiac, pulmonary, neurologic or psychiatric disease lifeVaccination within 4 weeks before begin with study medication pregnant or breastfeeding weight under 45kg or more than 110kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>primary Sjogren´s Syndrome</keyword>
	<keyword>Cyclosporine</keyword>
</DOC>